Childhood Fructoholism and Fructoholic Liver Disease by Ribeiro, A. et al.
44
Hepatology CommuniCations, Vol. 3, no. 1, 2019  
Childhood Fructoholism and Fructoholic 
Liver Disease
Andreia Ribeiro,1 Maria-Jose Igual-Perez,1 Ermelinda Santos Silva,2 and Etienne M. Sokal 1
Nonalcoholic fatty liver disease (NAFLD) is an emerging entity, becoming the most prevalent pediatric chronic liver 
disease. Its broad spectrum of histological findings, comorbidities, and complications, including cirrhosis and liver 
failure, can occur in childhood, emphasizing the severity of pediatric NAFLD. Current lifestyle and diet modifica-
tions have been linked to the increasing prevalence of NAFLD, including the rise of fructose consumption, a mono-
saccharide present in foods that contain added sugar, such as sugar-sweetened beverages. Excessive fructose 
consumption is believed to cause addiction like alcohol and other drugs. As such, the new term “fructoholism” refers 
to the consumption of a substance (fructose) that can cause psychological and physical damage and become a major 
public health concern, highlighting the seriousness of the excessive consumption of fructose in the pediatric age. 
Hepatic fructose metabolization leads to hepatic steatosis and progression to fibrosis through mechanisms comparable 
to alcoholic liver disease, hence the term “fructoholic liver disease.” Conclusion: The importance of implementing reli-
able global strategies, such as education campaigns to promote healthy diet, increasing taxes on foods that contain 
added sugars, subsidies to promote accessibility to fruit and vegetables, and strict food industry regulation to reduce 
sugar intake in children and adolescents, cannot be overemphasized. (Hepatology Communications 2019;3:44-51).
During the past century, modifications in lifestyle and nutrition have contributed to an increase in noncommunicable diseases. 
Nonalcoholic fatty liver disease (NAFLD) has 
emerged as the most prevalent chronic liver disease, 
paralleling the worldwide increase of obesity, in the 
pediatric age.(1,2) NAFLD includes a spectrum of 
hepatic histological alterations, which are diagnosed 
based on the presence of at least 5% of hepatocytes 
with fatty infiltration with no evidence of infection, 
metabolic or autoimmune disorder, or steatogenic 
drug or alcohol consumption.(3,4) NAFLD can prog-
ress to nonalcoholic steatohepatitis (NASH), which is 
histologically characterized by the presence of steato-
sis and lobular inflammation with hepatocyte dam-
age.(3-5) NAFLD can potentially evolve to fibrosis, 
end-stage liver disease, and hepatocellular carcinoma 
(HCC).(3-5) Today, it is recognized as the hepatic 
manifestation of metabolic syndrome, being linked to 
obesity, insulin resistance, dyslipidemia, and cardio-
vascular disease.(6)
Fructose is a monosaccharide that is present in foods 
that contain added sugar components and has been 
linked to the rising incidence of obesity, insulin resis-
tance, and NAFLD in the pediatric population.(7,8) Its 
metabolism may parallel that of alcohol, with the pro-
duction of similar subproducts and liver damage.(9,10) 
Fructose consumption has increased 300% in the past 
20 years, and it may have an addictive effect similar to 
other drugs.(11) Therefore, banning added sugars from 
children’s diets should be considered a public health 
priority.
Abbreviations: DA, dopamine; DNL, de novo lipogenesis; FA, fatty acid; HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver 
disease; and NASH, nonalcoholic steatohepatitis.
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The aim of this review is to provide evidence of the 
negative effect of high fructose consumption in child-
hood on future liver health, with many similarities to 
alcohol, and to propose strategies for its reduction and 
to support global health improvement in the pediatric 
age.
Natural History of Pediatric 
NAFLD
NAFLD, initially thought to be a disease of adult-
hood, is increasingly recognized as an emerging and 
harmful entity in the pediatric age.(12) Biopsy is still 
the gold standard for diagnosis and accurate evaluation 
of fibrosis progression, which limits precise follow-up 
due to its invasiveness and potential risk conjugated 
with the absence of impact in therapy management.(13) 
Although NAFLD is the most common cause of ele-
vated liver enzymes, alanine aminotransferase and 
aspartate aminotransferase cannot be considered a 
reliable method for diagnosis and follow-up,(4,6) with 
several studies confirming all ranges of hepatic fibrosis 
in the presence of normal liver enzymes.(1,14-16)
Some studies revealed that NAFLD might begin in 
utero. Neonates born to obese mothers have a higher 
prevalence of liver steatosis compared with newborns 
from normal weight mothers, which can be a sign of 
early metabolic programming for a future with the 
trend to metabolic syndrome.(17,18) Despite the diffi-
culty of ascertaining the mean age of disease onset, 
most children are diagnosed in the second decade of 
life, with a slight male predominance.(14,19,20) A retro-
spective study of autopsied children 2 to 19 years of 
age from 1993 to 2003 showed the presence of fatty 
liver in 13%, with an increased prevalence with age 
(0.7% for 2-4 years old and 17.3% for 15-19 years 
old).(21) With the exponential increase in fructose 
consumption and pediatric obesity since this period, 
it is expected that this number might be higher today. 
Obesity is the main risk factor for pediatric NAFLD, 
with prevalence rising up to 80% in some coun-
tries.(3,12,13,15) Despite being more frequent in over-
weight children, NAFLD also occurs in children of 
normal weight.(14)
As described in adult cohorts, pediatric NAFLD 
has been associated with comorbidities affecting 
other organs, enhancing its multisystemic metabolic 
dysfunction.(20) Comorbidities detected in childhood 
include cardiovascular disease (hypertension and left 
ventricular disfunction), metabolic impairment (low 
mineral bone density, insulin resistance with progres-
sion to type 2 diabetes mellitus, hypercholesterolemia, 
and hypertriglyceridemia), and pulmonary (obstruc-
tive sleep apnea) and psychosocial affection.(19,20) 
The latter should not be neglected, as it has a nega-
tive effect on a child’s quality of life and adherence to 
treatment.(22) Feldestein et al. demonstrated that 83% 
of children with NAFLD have at least one character-
istic of metabolic syndrome, and 29% have established 
metabolic syndrome (three or more features).(19) Due 
to the broad spectrum of comorbidities associated 
with NAFLD, patients should be closely followed.
Recent data provide evidence of the heterogeneity 
of NAFLD progression in the pediatric age.(19) The 
whole spectrum of NAFLD can be seen in child-
hood, from liver steatosis to cirrhosis, to liver fail-
ure and HCC.(16) Although rare, rapid progression 
to cirrhosis and end-stage liver disease can disclose 
within a few years, and cirrhosis at diagnosis has also 
been described in childhood.(19,20,23,24) Surprisingly, 
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NAFLD has revealed to be more deleterious than 
hepatitis C virus (HCV) infection. Pediatric HCV 
progresses to cirrhosis in 1% to 4% of children during 
a period of 2 to 9 years, which contrasts with the rise 
of cirrhosis due to NAFLD.(25,26)
In the United States, NAFLD is the second indi-
cation for liver transplantation in the adult popula-
tion and is expected to become the leading cause 
in the upcoming years.(27,28) The recent increase in 
transplantation before the age of 40 may express the 
natural evolution of a childhood NAFLD onset.(29) 
Moreover, taking into account the ongoing rise of 
fructose consumption and childhood obesity and its 
role in NAFLD, a significative number of children 
might need liver transplantation and at earlier ages if 
no effective measures are assumed.(30,31) NASH recur-
rence in allograft with requirement of retransplanta-
tion is well recognized and can occur within a few 
months after transplantation if no solid lifestyle mod-
ification is attempted.(19,20,32,33)
In adults, NAFDL is clearly associated with HCC 
even without the presence of significant fibrosis.(34) 
Despite its rarity in the pediatric age range, HCC has 
been described in a 7-year-old boy with NAFLD, and 
childhood obesity raises the risk of HCC in adult-
hood.(20,35) The increase in pediatric severe NAFLD 
could raise the incidence of HCC in the young adult 
in the near future, strongly affecting NAFLD out-
come due to the low survival rate of HCC.(36)
Pediatric NAFLD is associated with a lower 
long-term survival as compared with the general 
population of the same age and sex, with a 13.8-
fold higher mortality risk.(19) In the pediatric age, 
it is not clear which patients have an augmented 
risk of progression and shorter survival, but the 
evidence of a more aggressive disease in childhood 
than previously thought emphasizes the importance 
of systematic follow-up. Pediatric NAFLD is a seri-
ous condition that should earn the attention of all 
clinicians to implement a reliable strategy to reduce 
morbidity and mortality seen in this population.
Fructose as the Main Cause 
of NAFLD
Fructose is the major constituent of common sweet-
eners, such as sucrose (table sugar), high fructose corn 
syrup, and agave syrup, which consist of a mixture of 
fructose and glucose monosaccharides.(30) Fructose 
consumption has risen uncontrollably over the past 
century, especially by ingestion of sugar-sweetened 
beverages.(30) It can also be found in fruits and honey, 
although with less noxious outcome than fructose in 
added sugar compounds due to its lower concentra-
tion and the presence of other constituents (primar-
ily antioxidants and fibers) that alter its metabolic 
effect.(30,31) Added sugars account for 15% of overall 
energy intake in the Western diet and are even higher 
among adolescents.(30) Despite the World Health 
Organization’s recommendation of reduction of free 
sugar intake to less than 10% of total calorie intake, 
US adolescents ingest an average of 94 g of added 
sugar per day (17.9% of energy intake).(37,38)
Fructose and glucose have considerably different 
metabolic pathways. Fructose enters in portal circu-
lation and is totally metabolized in the liver, whereas 
glucose is partially metabolized in the liver and 
tends to enter into systemic circulation.(31) Fructose 
hepatic metabolization to fructose-1-phosphate by 
fructokinase in glycolysis induces a fast depletion 
of adenosine triphosphate and increase of adenos-
ine monophosphate, which is converted to inosine 
monophosphate with acid uric production.(31,39,40) 
This transient decrease of adenosine triphosphate 
does not occur with glucose metabolization and 
is the key to fructose-mediated negative meta-
bolic effects. One of those effects is intrahepatic 
lipid accumulation (steatosis) due to an increase in 
hepatic fatty acid (FA) synthesis from de novo lipo-
genesis (DNL), an increase in hepatic delivery of 
FAs, and a decrease in lipid clearance.(30,31) Dietary 
sugars have been shown to enhance hepatic DNL, 
a metabolic pathway that affects lipid and glucose 
regulation and induces insulin resistance, cardio-
vascular disease, and hepatic steatosis.(8,41) Hepatic 
fructose metabolism results in available substrate 
to DNL and enhancement of regulatory signals to 
promote hepatic lipid synthesis, leading to serum 
triglycerides rising after acute fructose ingestion.(42) 
Additionally, chronic fructose intake leads to up-reg-
ulation of the DNL path with continuing overex-
pression of key transcription factors.(43) In patients 
with NAFLD, DNL was shown to be 3-fold greater 
than in healthy individuals.(44) Furthermore, high 
fructose intake with consequent adenosine triphos-
phate depletion and uric acid formation inhibits 
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enoyl coenzyme A (CoA) hydratase activity with 
consequent decrease of FA beta-oxidation, which 
leads to hepatic lipid accumulation and gluconeo-
genesis.(30,31) Oxidative stress, an important factor 
for liver steatosis progression to NASH, is induced 
by uric acid produced in fructose metabolism.(31) 
Another potential mechanism of fatty liver induc-
tion is related to the interaction of fructose with 
gut microbiome. Fructose metabolism in the gut by 
intestinal fructokinase leads to tight-junction dis-
ruption, resulting in increased gut permeability and 
endotoxins translocation into portal vein and, con-
sequently, increased oxidative stress.(45,46) Children 
with NAFDL have been shown to have elevated 
serum endotoxins levels and different microbiome 
profile when compared with controls, with more 
significant endogenous alcohol production and gen-
eration of hepatic oxidative stress.(47,48)
Fructose intake has a dose-dependent correla-
tion with NAFLD development and its progression 
to fibrosis in children and adolescents.(30) A study 
including 271 obese adolescents with biopsy-proven 
NAFLD showed that fructose consumption was sig-
nificantly higher in patients with NASH compared 
with NAFLD, and patients from the first group 
had significantly higher uric acid levels.(49) Short-
term fructose-restricted diet in obese children has 
demonstrated to decrease liver fat, visceral fat and 
DNL, and improve insulin kinetics—regardless of 
the calories consumed.(50) Furthermore, long-term 
(6-month) fructose restriction was associated with 
improvement of serum markers of liver dysfunction 
and cardiometabolic risk, with significant reduction 
of systolic blood pressure, alanine aminotransferase 
levels, Apolipoprotein-B100, and homeostasis model 
assessment of insulin resistance.(51) Adherence to the 
Mediterranean diet, characterized by high monoun-
saturated FAs and low fructose, was associated with 
a decrease in insulin resistance and liver inflam-
mation in pediatric patients with biopsy-proven 
NAFLD.(52)
NAFLD in childhood has been demonstrated to 
have different characteristics from adults, primarily 
concerning histological findings with a predominant 
periportal inflammation in the pediatric age.(4) Dietary 
fructose consumption with consequent hyperuricemia 
has been shown to induce greater damage in the peri-
portal zone than the perivenous zone.(39)
Sugar as a Cause of 
Addiction
Traditionally, the term “addiction” is reserved for 
drugs of abuse, such as cocaine, morphine, heroin, 
nicotine, and alcohol. Nevertheless, non–drug-related 
addictions have been investigated recently, includ-
ing gambling, sex, and food.(53) Sugar addiction is a 
specific type of food addiction, probably occurring 
due to its palatability combined with its postingestive 
effects.(54)
Sugar addiction from the viewpoint of behavior 
and brain neurochemistry has been shown in animal 
models, in which feeding comportment during inter-
mittent access to sugar solutions was studied, demon-
strating similar addiction-related behaviors caused by 
drugs of abuse, including bingeing, withdrawal syn-
drome, cravings, and cross-sensitization.(55) Rats’ pref-
erence for sugar reward over an addictive drug such 
as cocaine has been evidenced, even for rats that are 
cocaine-dependent.(56) These effects may occur due to 
the same neural circuits involved in these consumma-
tory behaviors for drugs of abuse and sugar, causing 
dopaminergic, cholinergic, and opioid effects.(55)
Two neural pathways have been implicated in 
energy intake and reward in the brain: the homeo-
static system, which regulates feeding based on 
energy need; and the hedonic system, which is 
involved in “reward” and pleasure effects.(55) The 
ventral tegmental area and nucleus accumbens are 
the structures of the hedonic system implicated in 
the “reward” of food intake.(57) The dopaminergic 
effect is caused by a dopamine (DA) increase in the 
nucleus accumbens; DA receptors may change its 
expression or availability for the substance inducing 
release of DA or decrease of DA reuptake, the effect 
of most substances of abuse.(11,58,59) Sugar addiction 
also appears to be opioid-mediated. After repeated 
exposure to sugar, rats exposed to naloxone, an opi-
oid antagonist that chemically blocks the synaptic 
receptor, showed withdrawal symptoms similar to 
that observed in mice that are chronically exposed 
to opioids drugs, leading to anxiety and behavioral 
depression similar to nicotine or morphine.(60,61) 
This effect appears to be due to opioids’ modifi-
cations and concerns two neurochemical manifes-
tations: extracellular DA decrease in the nucleus 
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accumbens and acetylcholine release from the 
nucleus accumbens interneurons.(62) The cerebral 
cholinergic system is related to DA and the opioids 
system, and is implicated in food and drug intake, 
decreasing satiety when extracellular acetylcholine 
concentration is high and DA is low.(63,64) All of 
these neurochemical findings, comparing the effects 
of sugar and drugs of abuse in the brain and behav-
ior, may explain sugar dependency.
Fructose and Ethanol 
Similarities
Excessive alcohol intake is considered a drug of 
abuse, and its consumption entails a high-risk factor 
for chronic liver disease pathogenesis, such as ste-
atosis, cirrhosis, and HCC.(65) In addition to their 
similar addictive effect, fructose and ethanol share 
analogies in liver metabolism (Fig. 1).(9) They are 
both substrates for the DNL pathway, leading to 
FA synthesis, dyslipidemia, and hepatic steatosis.(9) 
In the hepatocyte, ethanol is metabolized to acet-
aldehyde, which is transformed in acetic acid and 
then metabolized in acetyl-CoA, which partici-
pates in FA synthesis through DNL.(66) Ethanol 
also causes microsomal triglyceride transfer protein 
suppression, increasing very low-density lipopro-
tein production and exportation, which contributes 
to hypertriglyceridemia and insulin resistance, as 
does fructose.(9) In a comparable way as fructose 
metabolism, ethanol leads to reactive oxygen spe-
cies production due to its hepatic metabolization to 
acetaldehyde.(66-68) Consequently, this can promote 
hepatocellular damage as lipid peroxidation, fibro-
genesis, and cirrhosis.(67-69) Thus, metabolites from 
alcohol metabolism are comparable to those result-
ing of fructose metabolism, which leads to identical 
toxic cellular response and hepatocyte damage.
In conclusion, several data showed that fructose 
consumption is the primary cause of NAFLD, with 
Fig. 1. In hepatic fructose metabolism, the major part of fructose is metabolized directly to pyruvate. Due to the liver mitochondria 
cannot metabolizing the substrate excess, there is an overproduction of DNL and VLDL (very-low-density lipoprotein), which is 
exported out of the liver to contribute to fructose-induced hypertriglyceridemia. Fructose induces substrate-dependent phosphate 
depletion, which increases uric acid contributing to the decrease of FA ß-oxidation, leading to intrahepatic lipid accumulation, and 
it is also primarily responsible for the oxidative stress. Fructose also stimulates the overexpression of key transcription factors, which 
lead to up-regulation of DNL as ChREBP (carbohydrate response element binding protein) and PGC-1ß (peroxisomal proliferator-
activated receptor-γ coactivator-1ß). PGC-1ß is a transcriptional coactivator for SREBP-1c (sterol regulatory element binding protein-
1c), which accentuates DNL enzymatic activity, and JNK-1 (c-jun N-terminal kinase), which, once is induced, begins the inf lammation 
cascade. As part of its inf lammatory action, JNK-1 activation induces IRS-1 (insulin receptor substrate-1), which promotes hepatic 
insulin resistance. In hepatic alcohol metabolism, ethanol is metabolized to acetaldehyde, which, because of its free aldehyde, can 
generate ROS (reactive oxygen species) formation and toxic damage. Furthermore, acetaldehyde stimulates SREBP-1c, activating the 
enzymes of DNL and JNK-1, promoting the inf lammation process and hepatic insulin resistance by inducing IRS-1. In the ethanol 
metabolization process there is an excess of the product intermediaries, which stimulates an overproduction of DNL, resulting in 
further intrahepatic lipid build-up. By suppressing the activity of the protein that mediates the VLDL production, ethanol intake 
contributes to hypertriglyceridemia.
Hepatology CommuniCations, Vol. 3, no. 1, 2019 RibeiRo et al.
49
a dose-dependent effect leading to a pattern of liver 
injury comparable to alcohol ingestion. Additionally, it 
has been shown that excessive sugar intake may cause 
similar addiction behavior. Because of the negative 
effects of fructose described in children’s health, the 
authors suggest that excessive fructose consumption 
can be compared with alcohol intake in adults, lead-
ing to the term “fructoholism”—the consumption of a 
substance (fructose) that can cause psychological and 
physical damage, and fructoholic liver disease. Using 
these terms, the authors highlight the importance of 
taking seriously the fructose intake in the pediatric 
age and developing an active response to this problem.
Possible Strategies for 
Preventing Excessive Sugar 
Intake
It is imperative to adopt measures at different 
levels that could support the reduction of sugar 
intake in the population, especially in the youngest 
and most vulnerable community, such as children. 
Despite the existence of several ongoing clinical tri-
als, there is no effective pharmacological treatment 
for pediatric NAFLD, with lifestyle intervention 
remaining the first line of treatment.(70) Avoidance of 
sugar-sweetened beverages, increase in daily physical 
activity, a healthy and well-balanced diet, and limita-
tions on screen time activities to fewer than 2 hours 
per day are among the most recommended ones.(4) 
Moreover, to achieve successful lifestyle change, it is 
important to take into consideration family involve-
ment and a solid interaction with primary care. The 
Mediterranean diet, consisting of vegetables, fruits, 
primarily unrefined cereals, olive oil and fish, has 
been studied as an appropriate therapeutic option 
for patients with NASH, because of its increase in 
monosaturated FAs and decrease in saturated fat and 
cholesterol, along with a high content of complex 
carbohydrates and fibers.(52,71)
Finally, it is imperative to contemplate public policy 
measures and to raise awareness of public institutions 
about the importance of limiting fructose intake, as 
this is a real public health problem. The authors pro-
pose the following potential strategies, some of which 
have already been implemented successfully:
• Food education at school to promote knowl-
edge about nutrients and the proper combina-
tion of them to achieve a healthy diet, along 
with the importance of physical exercise.
• Distribution of fruits and vegetables at schools 
to promote the benefits of a healthy diet and to 
encourage their consumption, which is already 
done in some countries of the European Union 
through the “EU school fruit, vegetable, and 
milk scheme” program.(72)
• Promotion of a healthy diet through education 
campaigns and favoring its consumption using, 
for instance, vending machines in strategical 
places, such as train stations or airports.
• Increasing taxes on foods that contain any form 
of added sugar (processed foods, juices, and 
soft drinks), like some countries have already 
done with foods high in saturated fat.(73,74) 
The World Health Organization, through the 
Global Action Plan for the Prevention and 
Control of Noncommunicable Diseases 2013-
2020, considers adding taxes and subsidies to 
promote accessibility to healthier food (with 
lower prices) and discourage the consumption 
of less healthy products.(75)
• Regulation of the amount of sugars added by 
food industries as well as the regulation of the 
type of sugar they are allowed to use and dis-
crimination of sugar quantity in all products.
In conclusion, NAFLD is an emerging entity in 
the pediatric age, becoming the most prevalent pe-
diatric chronic liver disease. The increasing prev-
alence of NAFLD is linked to the rise of fructose 
consumption, which causes a comparable pattern of 
liver injury to alcohol consumption and is believed to 
have a similar addiction effect, named by the authors 
as “fructoholism,” potentially leading to “fructoholic 
liver diseases.” It is imperative to consider the impor-
tance of different approaches to limit sugar consump-
tion and its health consequences and raise society’s 
awareness of this public health problem, especially in 
the youngest and most vulnerable population.
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